However, Blueprint took an important measure to make sure their pipeline becomes successful. If Blueprint wants to become a mature biotech company, as the current valuation suggests, then success across the entire current pipeline is necessary. As an example, ATVAKIT is only expected to bring in between $115 to $130 million in 2022, far less than current operating costs. This is because the initial target populations are not sufficient to drive blockbuster status revenues. The success of expanded indications and novel therapies targeting new regions are necessary for continued growth. Also, data for expanded indications seem to be successful, increasing the probability of success for late-stage trials. As one RET-focused and one KIT-focused therapy have been approved, we can see that Blueprint's proprietary research is working well. While rare in terms of patient numbers, targeting one specific region helps to increase the effectiveness of treatment. However, Blueprint looks for an advantage with specification on a particular subset of "RET" and "KIT" therapies. Early-Stage: 4 trials, including a few recent acquisitions of varied platforms.īlueprint's narrow pipeline is focused on targeting kinase mutations with inhibitors, a fairly common approach.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |